Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

738.00 -6.50 (-0.87%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
42 43 Next >
Europe Approves First Bispecific Antibody From Roche For Two Eye Disorders
Via Benzinga
WHO Recommends Against Roche, GSK's COVID-19 Therapies Rendering Them Obsolete
Due to the lack of effectiveness against omicron and the variants, World Health Organization (WHO) no longer recommends using two COVID-19 antibody therapies. 
Via Benzinga
Intellia Therapeutics Posts Back To Back Positive Data From Gene Editing Therapies
Via Benzinga
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema. 
Via Investor's Business Daily
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
Via Benzinga
Regeneron's Bispecific Antibodies Show Encouraging Anti Tumor Activity
Via Benzinga
Analyst Ratings for Regeneron Pharmaceuticals
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings: 
Via Benzinga
Regeneron Stock Soars On Pair Of Successful Trials
Studies "support aflibercept 8 mg as a potential new standard-of-care," the drugmaker said. 
Via Investor's Business Daily
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why. 
Via Investor's Business Daily
Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers
Via Benzinga
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
Via Benzinga
ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients
Via Benzinga
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it."  The... 
Via Benzinga
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says
Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati 
Via Benzinga
Why These 3 Stocks Are Off to Hot September Starts
Let’s look at what is behind the surprise rise in these three names—and whether they can continue to pace this month’s market rally. 
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
9 Analysts Have This to Say About Regeneron Pharmaceuticals
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter: 
Via Benzinga
Jefferies Upgrades Regeneron Pharmaceuticals: Here's What You Need To Know
Jefferies upgraded its rating of Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold with a price target of $675.00, changing its price target from $536.00 to $675.00. Shares of Regeneron Pharmaceuticals... 
Via Benzinga
'Highly Compelling' Eye Drug Data Has Wall Street Stampeding To Buy This 'Large Cap Growth Story.' Even After $15B In Market Cap Was Added
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Upgrades 
Via Benzinga
What 9 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
Over the past 3 months, 9 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
Regeneron Pharmaceuticals To $851? Here Are 5 Other Price Target Changes For Friday
Morgan Stanley raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from $625 to $851. Morgan Stanley analyst Matthew Harrison also upgraded the stock from Equal-Weight to... 
Via Benzinga
US Stock Futures Surge; Fed Speakers In Focus
Pre-open movers U.S. stock futures traded higher in early pre-market trade after recording gains on Thursday. The Dow Jones jumped around 193 points, while the Nasdaq Composite climbed 0.6% in the... 
Via Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
Via Benzinga
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to... 
Via Benzinga
Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease
Via Benzinga
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders. 
Via Benzinga
AeroVironment, Snap And Some Other Big Stocks Moving Higher On Thursday
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug
Via Benzinga
Regeneron Pharmaceuticals Whale Trades For September 06
Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on... 
Via Benzinga
Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids
Via Benzinga
< Previous 1 2
...
23 24 25 26 27 28 29 30 31
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.